Stereolability of Dihydroartemisinin, an Antimalarial Drug: A Comprehensive Kinetic Investigation. Part 2

详细信息    查看全文

• 作者：Walter Cabri ; Ilaria D鈥橝cquarica ; Patrizia Simone ; Marta Di Iorio ; Michela Di Mattia ; Francesco Gasparrini ; Fabrizio Giorgi ; Andrea Mazzanti ; Marco Pierini ; Marco Quaglia ; Claudio Villani
• 刊名：Journal of Organic Chemistry
• 出版年：2011
• 出版时间：June 17, 2011
• 年：2011
• 卷：76
• 期：12
• 页码：4831-4840
• 全文大小：1061K
• 年卷期：v.76,no.12(June 17, 2011)
• ISSN：1520-6904

文摘

Artemisinin or qinghaosu has now largely given way to the more potent dihydroartemisinin (DHA, 1) and its derivatives in the treatment of drug-resistant malaria, in combination with other classical antimalarial drugs. DHA is obtained by NaBH₄ reduction of artemisinin and contains a stereochemically labile center at C-10, which provided two lactol hemiacetal interconverting epimers, namely 1伪 and 1尾. In the solid state, the drug consists exclusively of the 尾-epimer; however, upon dissolution, the two epimers equilibrate, reaching different solvent-dependent ratios with different rates. Such equilibration also occurs in vivo, irrespective of the isomeric purity at which the drug would have been administered. The aim of this study was then to achieve an in-depth understanding of the kinetic features of the 伪/尾 equilibration. To this purpose, free energy activation barriers (螖G) of the interconversion were determined as a function of both general and specific acid and base catalysts, ionic strength, and temperature in different solvents by dynamic HPLC (DHPLC). In hydro-organic media, the dependence of 螖G on temperature led to the evaluation of the related enthalpic and entropic contributions. Theoretical calculations suggested that the rate-determining step of the interconversion is not the ring-opening of the cyclic hemiacetal but the previous reversible deprotonation of the individual epimers (base-catalyzed mechanism). The whole findings may contribute to shed some light on the mechanism of action and/or bioavailability of the drug at the molecular level.